Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2008 1
2013 1
2014 1
2015 1
2017 2
2018 1
2019 3
2021 2
2022 2
2023 2
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

14 results

Results by year

Filters applied: . Clear all
Page 1
Impact of Thrombolytic Therapy on the Long-Term Outcome of Intermediate-Risk Pulmonary Embolism.
Konstantinides SV, Vicaut E, Danays T, Becattini C, Bertoletti L, Beyer-Westendorf J, Bouvaist H, Couturaud F, Dellas C, Duerschmied D, Empen K, Ferrari E, Galiè N, Jiménez D, Kostrubiec M, Kozak M, Kupatt C, Lang IM, Lankeit M, Meneveau N, Palazzini M, Pruszczyk P, Rugolotto M, Salvi A, Sanchez O, Schellong S, Sobkowicz B, Meyer G. Konstantinides SV, et al. Among authors: palazzini m. J Am Coll Cardiol. 2017 Mar 28;69(12):1536-1544. doi: 10.1016/j.jacc.2016.12.039. J Am Coll Cardiol. 2017. PMID: 28335835 Free article. Clinical Trial.
BACKGROUND: The long-term effect of thrombolytic treatment of pulmonary embolism (PE) is unknown. ...RESULTS: Long-term (median 37.8 months) survival was assessed in 353 of 359 (98.3%) patients in the thrombolysis arm and in 343 of 350 (98.0%) in the placebo arm. .. …
BACKGROUND: The long-term effect of thrombolytic treatment of pulmonary embolism (PE) is unknown. ...RESULTS: Long-term (media …
Long-term outcomes after pulmonary endarterectomy.
Dardi F, Manes A, Guarino D, Suarez SM, Loforte A, Rotunno M, Pacini D, Galiѐ N, Palazzini M. Dardi F, et al. Among authors: palazzini m. Ann Cardiothorac Surg. 2022 Mar;11(2):172-174. doi: 10.21037/acs-2021-pte-179. Ann Cardiothorac Surg. 2022. PMID: 35433360 Free PMC article. No abstract available.
Treatment goals of pulmonary hypertension.
McLaughlin VV, Gaine SP, Howard LS, Leuchte HH, Mathier MA, Mehta S, Palazzini M, Park MH, Tapson VF, Sitbon O. McLaughlin VV, et al. Among authors: palazzini m. J Am Coll Cardiol. 2013 Dec 24;62(25 Suppl):D73-81. doi: 10.1016/j.jacc.2013.10.034. J Am Coll Cardiol. 2013. PMID: 24355644 Free article. Review.
However, to more effectively prognosticate in the current era of complex treatments, it is becoming clear that the "bar" needs to be set higher, with more robust and clearer delineations aimed at parameters that correlate with long-term outcome; namely, exercise capacity a …
However, to more effectively prognosticate in the current era of complex treatments, it is becoming clear that the "bar" needs to be set hig …
Comparison of different treatment strategies in patients with chronic thromboembolic pulmonary hypertension: a single centre real-world experience.
Dardi F, Rotunno M, Guarino D, Suarez SM, Niro F, Loforte A, Taglieri N, Ballerini A, Magnani I, Bertozzi R, Donato F, Martini G, Manes A, Saia F, Pacini D, Galiè N, Palazzini M. Dardi F, et al. Among authors: palazzini m. Int J Cardiol. 2023 Nov 15;391:131333. doi: 10.1016/j.ijcard.2023.131333. Epub 2023 Sep 4. Int J Cardiol. 2023. PMID: 37673403
METHODS: All patients with CTEPH referred to our centre were included. We compare the short-term clinical, functional, exercise and haemodynamic effect of medical therapy (irrespective of subsequent treatment strategies), PEA and BPA (irrespective of previous/subsequent tr …
METHODS: All patients with CTEPH referred to our centre were included. We compare the short-term clinical, functional, exercise and h …
Recovery of right ventricular function after intermediate-risk pulmonary embolism: results from the multicentre Pulmonary Embolism International Trial (PEITHO)-2.
Mavromanoli AC, Barco S, Ageno W, Bouvaist H, Brodmann M, Cuccia C, Couturaud F, Dellas C, Dimopoulos K, Duerschmied D, Empen K, Faggiano P, Ferrari E, Galiè N, Galvani M, Ghuysen A, Giannakoulas G, Huisman MV, Jiménez D, Kozak M, Lang IM, Meneveau N, Münzel T, Palazzini M, Petris AO, Piovaccari G, Salvi A, Schellong S, Schmidt KH, Verschuren F, Schmidtmann I, Toenges G, Klok FA, Konstantinides SV; PEITHO-2 Investigators. Mavromanoli AC, et al. Among authors: palazzini m. Clin Res Cardiol. 2023 Oct;112(10):1372-1381. doi: 10.1007/s00392-022-02138-4. Epub 2022 Dec 21. Clin Res Cardiol. 2023. PMID: 36539534 Free PMC article. Clinical Trial.
Almost one in four patients, however, continued to have evidence of RV dysfunction over the long term....
Almost one in four patients, however, continued to have evidence of RV dysfunction over the long term....
Pulmonary arterial hypertension: guidelines and unmet clinical needs.
Giuggioli D, Bruni C, Cacciapaglia F, Dardi F, De Cata A, Del Papa N, Iannone F, Lunardi C, Maglione W, Molinaro F, Palazzini M, Spinella A, Tinazzi E, Matucci Cerinic M. Giuggioli D, et al. Among authors: palazzini m. Reumatismo. 2021 Jan 18;72(4):228-246. doi: 10.4081/reumatismo.2020.1310. Reumatismo. 2021. PMID: 33677950 Free article.
The term pulmonary arterial hypertension (PAH) identifies a heterogeneous group of diseases characterized by a progressive increase in pulmonary arterial resistance (PVR), which causes a significant burden in terms of quality of life, right heart failure and premature deat …
The term pulmonary arterial hypertension (PAH) identifies a heterogeneous group of diseases characterized by a progressive increase i …
[Treatment goals of pulmonary hypertension].
McLaughlin VV, Gaine SP, Howard LS, Leuchte HH, Mathier MA, Mehta S, Palazzini M, Park MH, Tapson VF, Sitbon O. McLaughlin VV, et al. Among authors: palazzini m. Turk Kardiyol Dern Ars. 2014 Oct;42 Suppl 1:95-105. Turk Kardiyol Dern Ars. 2014. PMID: 25697037 Turkish.
However, to more effectively prognosticate in the current era of complex treatments, it is becoming clear that the "bar" needs to be set higher, with more robust and clearer delineations aimed at parameters that correlate with long-term outcome; namely, exercise capacity a …
However, to more effectively prognosticate in the current era of complex treatments, it is becoming clear that the "bar" needs to be set hig …
The burden of comorbidities in pulmonary arterial hypertension.
Lang IM, Palazzini M. Lang IM, et al. Among authors: palazzini m. Eur Heart J Suppl. 2019 Dec;21(Suppl K):K21-K28. doi: 10.1093/eurheartj/suz205. Epub 2019 Dec 17. Eur Heart J Suppl. 2019. PMID: 31857797 Free PMC article.
The comorbidities discussed in this review (systemic hypertension, obesity, sleep apnoea, clinical depression, obstructive airway disease, thyroid disease, diabetes, and ischaemic cardiovascular event) were chosen based on their prevalence in patients with idiopathic PAH in the R …
The comorbidities discussed in this review (systemic hypertension, obesity, sleep apnoea, clinical depression, obstructive airway disease, t …
[Progress in the treatment of pulmonary vascular diseases].
Galiè N, Dardi F, Manes A, Palazzini M. Galiè N, et al. Among authors: palazzini m. G Ital Cardiol (Rome). 2021 Oct;22(10):781-792. doi: 10.1714/3666.36509. G Ital Cardiol (Rome). 2021. PMID: 34570112 Italian.
In pulmonary vascular diseases, the therapy cannot be considered as a simple prescription of medications and interventions but is a complex strategy which includes baseline patients' risk stratification, initial therapy, long-term follow-up and treatment adjustments when r …
In pulmonary vascular diseases, the therapy cannot be considered as a simple prescription of medications and interventions but is a complex …
Management of pulmonary arterial hypertension associated with congenital systemic-to-pulmonary shunts and Eisenmenger's syndrome.
Galie N, Manes A, Palazzini M, Negro L, Marinelli A, Gambetti S, Mariucci E, Donti A, Branzi A, Picchio FM. Galie N, et al. Among authors: palazzini m. Drugs. 2008;68(8):1049-66. doi: 10.2165/00003495-200868080-00004. Drugs. 2008. PMID: 18484798 Review.
One randomized controlled trial reported favourable short- and long-term outcomes of treatment with the orally active dual endothelin receptor antagonist bosentan in patients with Eisenmenger's syndrome. ...
One randomized controlled trial reported favourable short- and long-term outcomes of treatment with the orally active dual endothelin …
14 results